Qingxin Mu

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Venues

University of Washington

Shandong University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Washington Jun 04 2017

United States

Research Scientist :: Department of Pharmaceutics

University of Washington Jul 01 2016 - May 31 2017

United States

Acting Instructor :: Department of Materials Science and Engineering

Education History

Shandong University Sep 01 2005 - Jun 30 2010

China

PHD :: Pharmaceutical Science

Henan University Sep 01 2001 - Jun 30 2005

China

BSC :: Pharmaceutical Science

Publications

James I Griffin, Xinyue Chen, Luqi Duan, Qingxin Mu, Rodney J Y Ho
Inoculation of Pan02 cells produces tumor nodules in mouse pancreas: Characterization of a novel orthotopic pancreatic ductal adenocarcinoma tumor model for interventional studies. PloS one 19 (3) (2024)
Jesse Yu, Xiaolin Xu, James Ian Griffin, Qingxin Mu, Rodney J Y Ho
Drug Combination Nanoparticles Containing Gemcitabine and Paclitaxel Enable Orthotopic 4T1 Breast Tumor Regression. Cancers 16 (16) (2024)
James I Griffin, Xinyue Chen, Luqi Duan, Qingxin Mu, Rodney J Y Ho
Inoculation of Pan02 cells produces tumor nodules in mouse pancreas: Characterization of a novel orthotopic pancreatic ductal adenocarcinoma tumor model for interventional studies. PloS one 19 (3) (2024)
James I Griffin, Xinyue Chen, Luqi Duan, Qingxin Mu, Rodney J Y Ho
Inoculation of Pan02 cells produces tumor nodules in mouse pancreas: Characterization of a novel orthotopic pancreatic ductal adenocarcinoma tumor model for interventional studies. PloS one 19 (3) (2024)
Jesse Yu, Xiaolin Xu, James Ian Griffin, Qingxin Mu, Rodney J Y Ho
Drug Combination Nanoparticles Containing Gemcitabine and Paclitaxel Enable Orthotopic 4T1 Breast Tumor Regression. Cancers 16 (16) (2024)
James Ian Griffin, Yan Wu, Qingxin Mu, Xinyan Li, Rodney J Y Ho
Design and Characterization of a Novel Venetoclax-Zanubrutinib Nano-Combination for Enhancing Leukemic Cell Uptake and Long-Acting Plasma Exposure. Pharmaceutics 15 (3) (2023)
James Ian Griffin, Yan Wu, Qingxin Mu, Xinyan Li, Rodney J Y Ho
Design and Characterization of a Novel Venetoclax-Zanubrutinib Nano-Combination for Enhancing Leukemic Cell Uptake and Long-Acting Plasma Exposure. Pharmaceutics 15 (3) (2023)
James Ian Griffin, Yan Wu, Qingxin Mu, Xinyan Li, Rodney J Y Ho
Design and Characterization of a Novel Venetoclax-Zanubrutinib Nano-Combination for Enhancing Leukemic Cell Uptake and Long-Acting Plasma Exposure. Pharmaceutics 15 (3) (2023)
Zhiyong Wei, Qingxin Mu, Hui Wang, Guanyou Lin, Miqin Zhang
Enzymatic and Cellular Degradation of Carbon-Based Biconcave Nanodisks. Micromachines 13 (7) (2022)
Guanyou Lin, Qingxin Mu, Richard A Revia, Zachary Stephen, Mike Jeon, Miqin Zhang
A highly selective iron oxide-based imaging nanoparticle for long-term monitoring of drug-induced tumor cell apoptosis. Biomaterials science 9 (2) (2021)
Linxi Zhu, Qingxin Mu, Jesse Yu, James I Griffin, Xiaolin Xu, Rodney J Y Ho
ICAM-1 Targeted Drug Combination Nanoparticles Enhanced Gemcitabine-Paclitaxel Exposure and Breast Cancer Suppression in Mouse Models. Pharmaceutics 14 (1) (2021)
Qingxin Mu, Jesse Yu, James I Griffin, Yan Wu, Linxi Zhu, Lisa A McConnachie, Rodney J Y Ho
Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis. PloS one 15 (3) (2020)

Qingxin Mu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Qingxin Mu